Bayer AG and its subsidiary Asklepios BioPharmaceutical, Inc. (AskBio), have achieved a significant milestone in the fight against congestive heart failure (CHF) with the randomization of the first patient in the Phase II GenePHIT trial for AB-1002 (NAN-101). This trial represents a critical step forward in the development of new treatments for CHF, a condition […]
German pharma giant Bayer has agreed to acquire US clinical-stage gene therapy company Asklepios BioPharmaceutical in a deal worth up to $4 billion. The portfolio of Asklepios BioPharmaceutical features investigational pre-clinical and clinical stage candidates, which are being developed for the treatment of neuromuscular, cardiovascular, central nervous system, and metabolic diseases. Asklepios BioPharmaceutical was established […]
